Soluble Gamma-secretase Modulators Attenuate Alzheimer's β-amyloid Pathology and Induce Conformational Changes in Presenilin 1

被引:25
作者
Raven, Frank [1 ,2 ]
Ward, Joseph F. [1 ]
Zoltowska, Katarzyna M. [3 ]
Wan, Yu [1 ,4 ]
Bylykbashi, Enjana [1 ]
Miller, Sean J. [1 ]
Shen, Xunuo [1 ]
Choi, Se Hoon [1 ]
Rynearson, Kevin D. [5 ]
Berezovska, Oksana [3 ]
Wagner, Steven L. [5 ,6 ]
Tanzi, Rudolph E. [1 ]
Zhang, Can [1 ]
机构
[1] Harvard Med Sch, Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis MIND, Genet & Aging Res Unit,Dept Neurol, Charlestown, MA 02129 USA
[2] Univ Groningen, Groningen Inst Evolutionary Life Sci, NL-9747 AG Groningen, Netherlands
[3] Harvard Med Sch, Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis MIND, Alzheimer Res Unit,Dept Neurol, Charlestown, MA 02129 USA
[4] Qingdao Univ, Qingdao Municipal Hosp, Dept Neurol, Qingdao, Peoples R China
[5] Univ Calif La Jolla, Dept Neurosci, San Diego, CA 92093 USA
[6] VA San Diego Healthcare Syst, La Jolla, CA 92161 USA
关键词
Alzheimer's disease; beta-amyloid; beta-amyloid precursor protein; gamma-secretase; gamma-secretase modulator; Notch; TRANSGENIC MOUSE MODEL; PRECURSOR PROTEIN; SYNAPTOTAGMIN; IN-VIVO; A-BETA; DISEASE; APP; DEPOSITION; INHIBITOR; MEMBRANE;
D O I
10.1016/j.ebiom.2017.08.028
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A central pathogenic event of Alzheimer's disease (AD) is the accumulation of the A beta 42 peptide, which is generated from amyloid-beta precursor protein (APP) via cleavages by beta- and gamma-secretase. We have developed a class of soluble 2-aminothiazole gamma-secretase modulators (SGSMs) that preferentially decreases A beta 42 levels. However, the effects of SGSMs in AD animals and cells expressing familial AD mutations, as well as the mechanism of gamma-secretase modulation remain largely unknown. Here, a representative of this SGSM scaffold, SGSM-36, was investigated using animals and cells expressing FAD mutations. SGSM-36 preferentially reduced A beta 42 levels without affecting either alpha- and beta-secretase processing of APP nor Notch processing. Furthermore, an allosteric site was identified within the gamma-secretase complex that allowed access of SGSM-36 using cell-based, fluorescence lifetime imaging microscopy analysis. Collectively, these studies provide mechanistic insights regarding SGSMs of this class and reinforce their therapeutic potential in AD. (C) 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
引用
收藏
页码:93 / 101
页数:9
相关论文
共 54 条
[1]   Evidence of a Novel Mechanism for Partial γ-Secretase Inhibition Induced Paradoxical Increase in Secreted Amyloid β Protein [J].
Barnwell, Eliza ;
Padmaraju, Vasudevaraju ;
Baranello, Robert ;
Pacheco-Quinto, Javier ;
Crosson, Craig ;
Ablonczy, Zsolt ;
Eckman, Elizabeth ;
Eckman, Christopher B. ;
Ramakrishnan, Viswanathan ;
Greig, Nigel H. ;
Pappolla, Miguel A. ;
Sambamurti, Kumar .
PLOS ONE, 2014, 9 (03)
[2]   The Alzheimer-related gene presenilin 1 facilitates notch 1 in primary mammalian neurons [J].
Berezovska, O ;
Frosch, M ;
McLean, P ;
Knowles, R ;
Koo, E ;
Kang, D ;
Shen, J ;
Lu, FM ;
Lux, SE ;
Tonegawa, S ;
Hyman, BT .
MOLECULAR BRAIN RESEARCH, 1999, 69 (02) :273-280
[3]   Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses [J].
Bertram, Lars ;
Tanzi, Rudolph E. .
NATURE REVIEWS NEUROSCIENCE, 2008, 9 (10) :768-778
[4]   Amyloid-PET predicts inhibition of de novo plaque formation upon chronic γ-secretase modulator treatment [J].
Brendel, M. ;
Jaworska, A. ;
Herms, J. ;
Trambauer, J. ;
Roetzer, C. ;
Gildehaus, F-J ;
Carlsen, J. ;
Cumming, P. ;
Bylund, J. ;
Luebbers, T. ;
Bartenstein, P. ;
Steiner, H. ;
Haass, C. ;
Baumann, K. ;
Rominger, A. .
MOLECULAR PSYCHIATRY, 2015, 20 (10) :1179-1187
[5]   The amyloid-β rise and γ-secretase inhibitor potency depend on the level of substrate expression [J].
Burton, Catherine R. ;
Meredith, Jere E. ;
Barten, Donna M. ;
Goldstein, Margi E. ;
Krause, Carol M. ;
Kieras, Cathy J. ;
Sisk, Lisa ;
Iben, Lawrence G. ;
Polson, Craig ;
Thompson, Mark W. ;
Lin, Xu-Alan ;
Corsa, Jason ;
Fiedler, Tracey ;
Pierdomenico, Maria ;
Cao, Yang ;
Roach, Arthur H. ;
Cantone, Joseph L. ;
Ford, Michael J. ;
Drexler, Dieter M. ;
Olson, Richard E. ;
Yang, Michael G. ;
Bergstrom, Carl P. ;
McElhone, Kate E. ;
Bronson, Joanne J. ;
Macor, John E. ;
Blat, Yuval ;
Grafstrom, Robert H. ;
Stern, Andrew M. ;
Seiffert, Dietmar A. ;
Zaczek, Robert ;
Albright, Charles F. ;
Toyn, Jeremy H. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (34) :22992-23003
[6]   A three-dimensional human neural cell culture model of Alzheimer's disease [J].
Choi, Se Hoon ;
Kim, Young Hye ;
Hebisch, Matthias ;
Sliwinski, Christopher ;
Lee, Seungkyu ;
D'Avanzo, Carla ;
Chen, Hechao ;
Hooli, Basavaraj ;
Asselin, Caroline ;
Muffat, Julien ;
Klee, Justin B. ;
Zhang, Can ;
Wainger, Brian J. ;
Peitz, Michael ;
Kovacs, Dora M. ;
Woolf, Clifford J. ;
Wagner, Steven L. ;
Tanzi, Rudolph E. ;
Kim, Doo Yeon .
NATURE, 2014, 515 (7526) :274-U293
[7]   Evidence that the 42- and 40-amino acid forms of amyloid beta protein are generated from the beta-amyloid precursor protein by different protease activities [J].
Citron, M ;
Diehl, TS ;
Gordon, G ;
Biere, AL ;
Seubert, P ;
Selkoe, DJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (23) :13170-13175
[8]   γ-Secretase modulators reduce endogenous amyloid β42 levels in human neural progenitor cells without altering neuronal differentiation [J].
D'Avanzo, Carla ;
Sliwinski, Christopher ;
Wagner, Steven L. ;
Tanzi, Rudolph E. ;
Kim, Doo Yeon ;
Kovacs, Dora M. .
FASEB JOURNAL, 2015, 29 (08) :3335-3341
[9]   Lessons from a Failed γ-Secretase Alzheimer Trial [J].
De Strooper, Bart .
CELL, 2014, 159 (04) :721-726
[10]   A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease [J].
Doody, Rachelle S. ;
Raman, Rema ;
Farlow, Martin ;
Iwatsubo, Takeshi ;
Vellas, Bruno ;
Joffe, Steven ;
Kieburtz, Karl ;
He, Feng ;
Sun, Xiaoying ;
Thomas, Ronald G. ;
Aisen, Paul S. ;
Siemers, Eric ;
Sethuraman, Gopalan ;
Mohs, Richard .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (04) :341-350